MedAvail Holdings, Inc. Common Stock
MDVL
MDVL was delisted on the 12th of February, 2024.
1 hedge funds and large institutions have $0 invested in MedAvail Holdings, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 20 closing their positions.
95% less funds holding
Funds holding: 21 → 1 (-20)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $334M → $0 (-$334M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 20
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$328M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$3.05M |
| 3 |
AWGLSCP
ABG-WTT Global Life Science Capital Partners
Central, Hong Kong,
Hong Kong
|
-$1.35M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$529K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$393K |
MDVL Hedge Fund Activity: Q1 2024 in Review
1 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in MedAvail Holdings, Inc. Common Stock (MDVL) for Q1 2024, worth a combined $0 — down 100% from $334M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of MDVL and 0 opened new positions — a net loss of 20 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Pura Vida Investments, exiting entirely with an estimated $328M sold.
- 1 institutional investor held MedAvail Holdings, Inc. Common Stock (MDVL) as of Q1 2024, down from 21 in Q4 2023.
- Funds reported $0 of MedAvail Holdings, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new MedAvail Holdings, Inc. Common Stock positions in Q1 2024 and 20 closed out, a net change of -20 holders.
- The largest MedAvail Holdings, Inc. Common Stock seller in Q1 2024 was Pura Vida Investments, an estimated $328M sold.
Based on aggregated 13F filings for Q1 2024.